The investigational monoclonal antibody, VYD2311, (Invivyd) met all primary and key secondary endpoints in the phase 3 LIBERTY study. It showed safety and tolerability superior to an mRNA-based ...
Invivyd reported statistically significant Phase 3 safety and tolerability results for VYD2311 compared with an mRNA-based COVID-19 vaccine and said it plans to pursue an Accelerated Approval BLA ...
Naples Daily News on MSN
Is it too early for influenza vaccine? Florida flu season starts this week
As flu and influenza-like illnesses rise across Florida, now is a good time to get vaccinated.
Andy Burnham's 'Your First Home' scheme is likely to boost homeownership and housebuilding, but comes with potential pitfalls ...
“The milestone marks another important step forward for the elritercept program,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. “We are grateful to our partner Takeda ...
October 1, 2026, 1:21-1:29 p.m. ET Industry-Supported Research Highlights | Presentation #149 CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results